XOMA and MURA Related Headlines
Go Back- XOMA completes acquisition of Mural Oncology for $2.035 per share
- XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
- XOMA Royalty completes acquisition of Mural Oncology
- Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
- Irish court approves XOMA Royalty's acquisition of Mural Oncology
- Mural Oncology Announces Sanction of the Scheme by the High Court
- Mural Oncology sets final cash payout at $2.035 per share for XOMA deal
- Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
- Mural Oncology shareholders approve XOMA Royalty acquisition
- Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
- XOMA to acquire Mural Oncology for up to $2.24 per share in cash
- Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
XOMA and MURA Related Press Releases
Go Back- XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
- Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
- Mural Oncology Announces Sanction of the Scheme by the High Court
- Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
- Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
- Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
